Preclinical Testing Of a Novel Axl-Kinase Inhibitor In Chronic Lymphocytic Leukemia
Maria Göbel, Michael Möllmann, André Görgens et al.
Key Points:
- Investigate two Axl inhibitors by their ability to inhibit migratory capacity and survival of leukemic cells
- In vitro studies showed: CLL patients with elevated sAxl plasma concentrations had shorter time to first treatment (p=0.0005) and several poor prognostic markers
- In vivo studies showed: In NSG mice, two Axl inhibitors, LDC2636 or BMS777607, reduced homing capacity of CLL cells to the BM by 46% and 59% respectively.
Implications:
- Axl inhibitors have activity against CLL cells, partly by suppression of CLL homing to their supportive stromal niches.
View the original abstract on the ASH website.
